All News

DPGN, lupus, nephritis, GN, glomerulonephritis, biopsy, kidney

Voclosporin Efficacy and Safety in Lupus Nephritis

Jack Cush, MD

An integrated analysis of two pivotal trials of voclosporin, a calcineurin inhibitor, in lupus nephritis patients saw significant improvement in complete renal responses (CRR) at one year.

Read Article
heart.EKG_.CVD_.jpg

Autoimmune Disease Augments Cardiovascular Risk

Jack Cush, MD

A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease.

Read Article
Bullous,SLE

Bullous Systemic Lupus Erythematosus

Jack Cush, MD

Bullous systemic lupus erythematosus (BSLE) is a rare blistering cutaneous manifestation of systemic lupus erythematosus (SLE).



As goes SLE, bullous disease typically affects women, especially those of African descent.

Read Article
RheumNow Podcast square

Managing JDM with Calcinosis

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow and discusses a case of refractory juvenile dermatomyositis with calcinosis.

Read Article
Malar,rash,SLE, Lupus

Low Dose IL-2 Therapy in SLE

Jack Cush, MD

A multicentre, proof-of-concept trial of suggests that low-dose IL-2 therapy may be effective in moderate-to-severe systemic lupus erythematosus (SLE).

Read Article
SCLE,DIL,PPI

Drug-Induced Lupus from Proton Pump Inhibitors

Jack Cush, MD

A wide range of therapies have been implicated in causing drug-induced lupus erythematosus (DIL); now it appears that proton pump inhibitors (PPIs) can be added to the list of causative drugs.

Read Article
Voclosporin Efficacy and Safety in Lupus Nephritis An integrated analysis of two pivotal trials of voclosporin, a calcineurin inhibitor, in lupus nephritis patients saw significant improvement in complete renal responses (CRR) at one year. https://t.co/LSjmRB2Zr3 https://t.co/z9MoJ0uRzz

Links:

Dr. John Cush RheumNow ( View Tweet)
ANA Increasing? Part of the NHANES survey, ANA (IIF on HEp-2 cells) was performed on 13,519 in 3 periods: 1988-1991, 1999-2004, and 2011-2012. ANA+ was 11% 1988-1991 11.4% 1999-2004 16.1% 2011-2012 (P <0.0001) Meaning ~22.3, ~26.6, &~41.5 mil had +ANAs https://t.co/vWYJci3uDV https://t.co/SEIbrYRoRJ

Links:

Dr. John Cush RheumNow ( View Tweet)
✅ Probably one of my most important slides ⬇️ WHY IS MY #TREATMENT NOT WORKING (or not working enough) 😭 This is really a question we're dealing with everyday in #rheumatology when taking care of patients with #autoimmune and other rheumatic diseases 👍 https://t.co/osUPYSvuWf
Laurent ARNAUD Lupusreference ( View Tweet)
Autoimmune Disease Augments Cardiovascular Risk A large UK database study suggests that young adults with autoimmune diseases have an associated increased risk for cardiovascular disease. https://t.co/TtiH9ZBkR8 https://t.co/jVZBk8l4XD

Links:

Dr. John Cush RheumNow ( View Tweet)
Phase 2 RCTs are evaluating TLR 7 & TLR 8 blockade in SLE - BMS has afimetoran and Merck has enpatoran (both blocking TLR7/8) https://t.co/lSvnAkRvxB https://t.co/i7ZORYyKHP

Links:

Dr. John Cush RheumNow ( View Tweet)
Learn how to manage lupus: 'The Lupus Encyclopedia: A Comprehensive Guide for Patients and Families' - on #BookBuzz - https://t.co/hvnoFRiabA

Links:

Donald Thomas, MD lupuscyclopedia ( View Tweet)

Chinese study of 215 Bx proven #SLE pts - all rx w/ IV CTX+steroids. Responders were given either AZA or leflunomide. Renal outcomes were same w/ LEF or AZA as maintenance. Flares (16% vs 18%), Time to flare (16 v 14 mos), AE, proteinuria https://t.co/Ad7Ec4OPco https://t.co/NoKAgiMKrK

Links:

Dr. John Cush RheumNow ( View Tweet)
Low Dose IL-2 Therapy in SLE A multicentre, proof-of-concept trial of suggests that low-dose IL-2 therapy may be effective in moderate-to-severe SLE. https://t.co/PNOp3Zdc8M https://t.co/B8DmUs5iuH

Links:

Dr. John Cush RheumNow ( View Tweet)
Urine-soluble CD163 as a biomarker in #SLE: usCD163 significantly higher w/ active lupus nephritis & correlates w/ UPCR, disease activity, anti-dsDNA Ab levels and a higher chronic kidney disease stage. https://t.co/gbSn0ZcFEK https://t.co/qjOSNvkIPC

Links:

Dr. John Cush RheumNow ( View Tweet)
Worldwide there are 484,213 #SLE cases in 2017 (7MM), with 54% in the USA (259,474 cases), the rest in the EU and Japan. Next most prevalent was UK (62,852) followed by Italy. Spain has lowest prevalence of SLE https://t.co/anRCYwrLoM https://t.co/nHbLzC0mSd

Links:

Dr. John Cush RheumNow ( View Tweet)
Medicare study of 10,868 Hospitalized lupus pts. Looking at age groups. 30 d rehospitalization higher in young adult LE (36%) - 40% higher than those without LE, 85% higher older LE. Rehospitalization higher with Longer hosp stay & higher comorbidity. https://t.co/Ul91DX6H8r https://t.co/t3plpQQ8qn

Links:

Dr. John Cush RheumNow ( View Tweet)
Rheums! Do you have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/cvmbzknQqA https://t.co/6mX5eRUNuU

Links:

Dr. John Cush RheumNow ( View Tweet)
Urine-soluble CD163 as a biomarker in #SLE: usCD163 significantly higher w/ active lupus nephritis & correlates w/ UPCR, disease activity, anti-dsDNA Ab levels and a higher chronic kidney disease stage. https://t.co/Mxe53pCnEF https://t.co/BOspodqpSE

Links:

Dr. John Cush RheumNow ( View Tweet)
Intensity and longevity of SARS-CoV-2 vaccination response in patients with immune-mediated inflammatory disease: a prospective cohort study https://t.co/1fiNgBQUbr looks like lower ab response and drops over 6 mths - boosters important in our patients

Links:

Peter Nash drpnash ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×